BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 31.54 CNY 2.1% Market Closed
Market Cap: 13.3B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

BrightGene Bio-Medical Technology Co Ltd
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BrightGene Bio-Medical Technology Co Ltd
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Other Operating Expenses
ÂĄ28.9m
CAGR 3-Years
43%
CAGR 5-Years
46%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Operating Expenses
-ÂĄ64.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Operating Expenses
ÂĄ32.1m
CAGR 3-Years
40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Operating Expenses
ÂĄ438.9m
CAGR 3-Years
24%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Operating Expenses
ÂĄ8.3m
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
-34%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Operating Expenses
ÂĄ49.1m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
13.3B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.57 CNY
Overvaluation 28%
Intrinsic Value
Price

See Also

What is BrightGene Bio-Medical Technology Co Ltd's Other Operating Expenses?
Other Operating Expenses
28.9m CNY

Based on the financial report for Dec 31, 2023, BrightGene Bio-Medical Technology Co Ltd's Other Operating Expenses amounts to 28.9m CNY.

What is BrightGene Bio-Medical Technology Co Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
46%

Over the last year, the Other Operating Expenses growth was 61%. The average annual Other Operating Expenses growth rates for BrightGene Bio-Medical Technology Co Ltd have been 43% over the past three years , 46% over the past five years .

Back to Top